JP2018516920A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516920A5
JP2018516920A5 JP2017561971A JP2017561971A JP2018516920A5 JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5 JP 2017561971 A JP2017561971 A JP 2017561971A JP 2017561971 A JP2017561971 A JP 2017561971A JP 2018516920 A5 JP2018516920 A5 JP 2018516920A5
Authority
JP
Japan
Prior art keywords
trastuzumab
administered
pharmaceutical
medicament
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017561971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516920A (ja
JP6822980B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/034835 external-priority patent/WO2016196373A2/en
Publication of JP2018516920A publication Critical patent/JP2018516920A/ja
Publication of JP2018516920A5 publication Critical patent/JP2018516920A5/ja
Priority to JP2021001246A priority Critical patent/JP7330217B2/ja
Application granted granted Critical
Publication of JP6822980B2 publication Critical patent/JP6822980B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017561971A 2015-05-30 2016-05-27 Her2陽性転移性乳癌の治療方法 Active JP6822980B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021001246A JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168809P 2015-05-30 2015-05-30
US62/168,809 2015-05-30
PCT/US2016/034835 WO2016196373A2 (en) 2015-05-30 2016-05-27 Methods of treating her2-positive metastatic breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001246A Division JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法

Publications (3)

Publication Number Publication Date
JP2018516920A JP2018516920A (ja) 2018-06-28
JP2018516920A5 true JP2018516920A5 (https=) 2019-07-04
JP6822980B2 JP6822980B2 (ja) 2021-01-27

Family

ID=56134616

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017561971A Active JP6822980B2 (ja) 2015-05-30 2016-05-27 Her2陽性転移性乳癌の治療方法
JP2021001246A Active JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法
JP2023064033A Withdrawn JP2023100635A (ja) 2015-05-30 2023-04-11 Her2陽性転移性乳癌の治療方法
JP2025105921A Pending JP2025157247A (ja) 2015-05-30 2025-06-23 Her2陽性転移性乳癌の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021001246A Active JP7330217B2 (ja) 2015-05-30 2021-01-07 Her2陽性転移性乳癌の治療方法
JP2023064033A Withdrawn JP2023100635A (ja) 2015-05-30 2023-04-11 Her2陽性転移性乳癌の治療方法
JP2025105921A Pending JP2025157247A (ja) 2015-05-30 2025-06-23 Her2陽性転移性乳癌の治療方法

Country Status (15)

Country Link
US (2) US11406715B2 (https=)
EP (1) EP3302551B1 (https=)
JP (4) JP6822980B2 (https=)
CN (1) CN107614015A (https=)
DK (1) DK3302551T3 (https=)
ES (1) ES2984592T3 (https=)
FI (1) FI3302551T3 (https=)
HR (1) HRP20241134T1 (https=)
HU (1) HUE068105T2 (https=)
LT (1) LT3302551T (https=)
PL (1) PL3302551T3 (https=)
PT (1) PT3302551T (https=)
RS (1) RS65871B1 (https=)
SI (1) SI3302551T1 (https=)
WO (1) WO2016196373A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330801A1 (en) * 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
US20200114018A1 (en) * 2018-10-15 2020-04-16 Genentech, Inc. Methods of treating residual breast cancer with trastuzumab emtansine
AU2019364258A1 (en) 2018-10-21 2021-06-03 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0950067B1 (en) 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2002507404A (ja) 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Apo−2リガンド−抗HER−2抗体相乗作用
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック, インコーポレイテッド 抗−ErbB2抗体による治療
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
JP2006516117A (ja) 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ErbB2抗体を用いた非悪性疾病または疾患の治療
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US7004206B2 (en) 2004-01-29 2006-02-28 Viken James P Automatic fluid exchanger
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド, ビー. エイガス, 疼痛治療のためのErbBアンタゴニスト
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Her2 항체 조성물
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Her阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
MY157955A (en) 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2009539836A (ja) 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド EGFまたはTGF−αのレベルの上昇が生じている癌患者の生存の延長
DK2056874T3 (da) 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
MX2009012838A (es) 2007-06-06 2009-12-11 Hoffmann La Roche Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
EP2260056A1 (en) 2008-03-06 2010-12-15 Genentech, Inc. Combination therapy with c-met and her antagonists
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
BR112013014316A2 (pt) 2010-12-09 2016-09-27 Genentech Inc tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1

Similar Documents

Publication Publication Date Title
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017226708A5 (https=)
JP2020509024A5 (https=)
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
RU2020120593A (ru) Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
JP2013155188A5 (https=)
JP2016530280A5 (https=)
JP2020523356A5 (https=)
JP2018522028A5 (https=)
JP2016515586A5 (https=)
JP2012522837A5 (https=)
JP2018526460A5 (https=)
JP2017514854A5 (https=)
JP2018516920A5 (https=)
RU2016147521A (ru) Способы применения антител к ang2
JP2019534251A5 (https=)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
JP2017524721A5 (https=)
WO2017142871A8 (en) Methods comprising fixed intermittent dosing of cediranib
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
FI3302551T3 (fi) Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
RU2015145948A (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
JP2020524164A5 (https=)